Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00330928 · ClinicalTrials.gov registry record · Phase 2
SPECTACL: SPECTroscopic Assessment of Coronary Lipid
A Phase 2 study, sponsored by Infraredx.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT00330928: Completed Phase 2 study, sponsored by Infraredx.
NCT00330928 is a Phase 2 study that has completed, run by Infraredx. The registered enrollment target is 106 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00330928, a Phase 2 study, has completed, sponsored by Infraredx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate a near-infrared (NIR) spectroscopy system that has been designed to identify the chemical composition of coronary artery plaques in patients undergoing a percutaneous coronary intervention (PCI).
Primary Outcome
Average spectral similarity of the spectra in a complete scan per patient as compared to the autopsy spectral data set.Clinical data was considered similar to autopsy data if average spectral similarity in each scan was \>=67%, on a continuous range of 0%(different) to 100%(identical) similarity.
Interventions
- DEVICE Near Infrared Spectroscopy (NIRS) Imaging
- DEVICE intravascular ultrasound (IVUS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
What the finished NCT00330928 record still lists
NCT00330928 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 2 interventions - of which Near Infrared Spectroscopy (NIRS) Imaging is the first listed.
NCT00330928 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00330928 about?
NCT00330928 is a clinical study titled "SPECTACL: SPECTroscopic Assessment of Coronary Lipid". The purpose of this study is to evaluate a near-infrared (NIR) spectroscopy system that has been designed to identify the chemical composition of coronary artery plaques in patients undergoing a percutaneous coronary intervention (PCI).
What is the current status of trial NCT00330928?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2006-01. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00330928?
The interventions under investigation include: Near Infrared Spectroscopy (NIRS) Imaging (DEVICE), intravascular ultrasound (IVUS) (DEVICE).
Who is sponsoring clinical trial NCT00330928?
This trial is sponsored by Infraredx, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00330928's enrollment target sits among peer trials
106 648th of 2000 higher than 1,351 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia